Crescent Biopharma (CBIO) Accumulated Expenses (2013 - 2026)

Crescent Biopharma (CBIO) has reported Accumulated Expenses for 14 consecutive years, with $7.4 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Accumulated Expenses fell 2.64% year-over-year to $7.4 million; the TTM figure through Jun 2026 stood at $7.4 million (down 2.64% YoY), while the FY2025 annual figure was $16.3 million, up 634.56% from the prior year.
• Accumulated Expenses grew to $7.4 million in Q2 2026 per CBIO's latest filing, from $4.4 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $16.3 million in Q4 2025 and bottomed at $2.2 million in Q4 2024.
• Historically, Accumulated Expenses has averaged $6.1 million across 5 years, with a median of $5.6 million in 2023.
• Annual changes were most pronounced in 2024 — Accumulated Expenses slumped 57.42% — and 2025, when it soared 634.56%.
• Crescent Biopharma's Accumulated Expenses stood at $7.0 million in 2022, then decreased by 25.26% to $5.2 million in 2023, then plunged by 57.42% to $2.2 million in 2024, then jumped by 634.56% to $16.3 million in 2025, then sank by 54.68% to $7.4 million in 2026.
• Business Quant data shows CBIO's Accumulated Expenses at $7.4 million in Q2 2026, $4.4 million in Q1 2026, and $16.3 million in Q4 2025.